welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc., a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor’s development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles.
The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted to CAP-1002 by the FDA, covers the broad treatment of DMD. Upon receiving market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.

rareRelated
-
Open-label Extension of the HOPE-2 TrialThis Phase 2, multi-center, open-label e...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
-
Capricor Therapeutics Expands Exosome Technology for DMDCapricor Therapeutics is expanding the d...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients With Duchenne Muscular Dystrophy Tr...Capricor Therapeutics, a clinical-stage ...